Document is current
Any future updates will be listed below
-
Authors
Ging-Jehli, Nadja R. https://orcid.org/0000-0002-1071-0693
Arnold, L. Eugene https://orcid.org/0000-0002-0886-0692
Van Zandt, Trish https://orcid.org/0000-0003-3576-0803
-
Funding
Funding for this research was provided by:
National Center for Translational Sciences to the Ohio State University (Clinical, Translational Science award 8UL18TR00)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P1SKP1_184033)
- License Information
-
More Information
Article History
Accepted: 13 September 2023
First Online: 3 October 2023
Declarations
:
: N. R. Ging-Jehli has received research funding from the Swiss National Science Foundation. L. E. Arnold has received research funding from Curemark, Forest, Lilly, Neuropharm, Novartis, Noven, Shire, Supernus, Roche, and YoungLiving (as well as NIH and Autism Speaks), has consulted with CHADD, Gowlings, Neuropharm, Organon, Pfizer, Sigma Tau, Shire, Tris Pharma, and Waypoint, and been on advisory boards for Arbor, Ironshore, Novartis, Noven, Otsuka, Pfizer, Roche, Seaside Therapeutics, Sigma Tau, Shire. This material is based on work performed by T. Van Zandt while serving at the National Science Foundation. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the National Science Foundation.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Institutional Review Board of The Ohio State University (Study Number: 2020B0085).
: Informed consent was obtained from all individual participants included in the study.
: Not applicable
Free to read: This content has been made available to all.
